Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) EVP Sells 30,000 Shares of Stock

Key Points

• Teva EVP Richard Daniell sold 30,000 shares on May 5 at an average price of $35.40 for a total of $1.062M, reducing his holdings by 34.98% to 55,755 shares (≈$1.97M).
• TEVA shares traded down 0.9% to $36.00 midday on heavy volume (~8.66M), with a market cap of $41.39B, a P/E of 27.07 and a one‑year range of $14.99–$37.35.
• Analysts maintain a consensus "Moderate Buy" with an average target of $41.78, and several firms (UBS, Goldman, Scotiabank, Barclays) have recently raised price targets into the $40–45 range.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) EVP Richard Daniell sold 30,000 shares of the stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $35.40, for a total transaction of $1,062,000.00. Following the transaction, the executive vice president owned 55,755 shares in the company, valued at approximately $1,973,727. This represents a 34.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Richard Daniell also recently made the following trade(s):

• On Thursday, March 5th, Richard Daniell sold 17,295 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $31.67, for a total transaction of $547,732.65.

Teva Pharmaceutical Industries Stock Down 0.9%

Shares of NYSE TEVA traded down $0.34 during midday trading on Thursday, reaching $36.00. 8,660,144 shares of the company's stock traded hands, compared to its average volume of 8,247,391. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. The stock's 50 day simple moving average is $31.24 and its 200-day simple moving average is $29.69. Teva Pharmaceutical Industries Ltd. has a one year low of $14.99 and a one year high of $37.35. The company has a market cap of $41.39 billion, a price-to-earnings ratio of 27.07, a P/E/G ratio of 3.47 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. The company had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. On average, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in TEVA. Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 2.2% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 45,956,714 shares of the company's stock worth $1,384,216,000 after purchasing an additional 1,004,941 shares during the last quarter. Phoenix Financial Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 9.4% during the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company's stock worth $834,164,000 after purchasing an additional 3,533,800 shares during the last quarter. Menora Mivtachim Holdings LTD. raised its holdings in shares of Teva Pharmaceutical Industries by 1.1% during the third quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company's stock worth $786,190,000 after purchasing an additional 427,000 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Teva Pharmaceutical Industries by 18.8% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company's stock worth $1,171,378,000 after purchasing an additional 5,917,423 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 14.8% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company's stock worth $1,167,323,000 after purchasing an additional 4,820,000 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Analysts Set New Price Targets

TEVA has been the subject of several recent analyst reports. Wall Street Zen downgraded shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "hold" rating in a research note on Saturday, May 2nd. Scotiabank raised their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a "sector outperform" rating in a research note on Thursday, January 29th. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a "buy" rating in a research note on Thursday, April 30th. The Goldman Sachs Group raised their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a "buy" rating in a research note on Monday, February 9th. Finally, Barclays raised their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an "overweight" rating in a research note on Wednesday. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $41.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.